psammaplysin A: cytotoxic psammaplysin analog from a Suberea sp. marine sponge; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44593641 |
| CHEMBL ID | 515023 |
| MeSH ID | M0589411 |
| Synonym |
|---|
| psammaplysin a |
| CHEMBL515023 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1894966 | Antiproliferative activity against human HCT-116 cells assessed as cell viability measured after 24 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis. |
| AID336280 | Cytotoxicity against human HCT116 cells | 1992 | Journal of natural products, Jun, Volume: 55, Issue:6 | Psammaplysin C: a new cytotoxic dibromotyrosine-derived metabolite from the marine sponge Druinella (= Psammaplysilla) purpurea. |
| AID341034 | Cytotoxicity against human HCT116 cells at 10 ug/mL by MTT assay | 2008 | Journal of natural products, Aug, Volume: 71, Issue:8 | Bioactive brominated metabolites from the Red Sea sponge Pseudoceratina arabica. |
| AID1894964 | Anticancer activity against human MDA-MB-231 cells assessed as cell viability measured after 24 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis. |
| AID1894965 | Antiproliferative activity against human HeLa cells assessed as cell viability measured after 24 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Discovery of cytotoxic natural products from Red Sea sponges: Structure and synthesis. |
| AID341032 | Antibacterial activity against Klebsiella pneumoniae ATCC 10032 assessed as inhibition zone at 1 mg after 24 hrs by agar diffusion method | 2008 | Journal of natural products, Aug, Volume: 71, Issue:8 | Bioactive brominated metabolites from the Red Sea sponge Pseudoceratina arabica. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||